Engineered immune cells target deadly brain tumors in new trial
NCT ID NCT07544992
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into the brain. The study aims to find the best dose and monitor side effects in 24 adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive beads take aim at brain tumours
- Gene-Edited immune cells take on aggressive brain tumors
- Targeted radiation delivered directly to brain tumor cavity in new trial
- Targeted radiation drug shows promise for tough brain tumors
- Radioactive antibody and immunotherapy combo targets recurrent brain cancer
- New brain cancer wafer shows promise in recurrent glioblastoma trial